Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.
about
Comparison of echinocandin antifungalsComedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity.Pharmacological advances in the treatment of invasive candidiasis.Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literatureTreatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.Echinocandins: role in antifungal therapy, 2005.Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.Caspofungin: an overview.Fungal infections in solid organ transplantation.Echinocandin antifungals: review and update.Emerging echinocandins for treatment of invasive fungal infections.Treatment options for invasive fungal infections.Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.The echinocandins.Invasive fungal infections and antifungal therapies in solid organ transplant recipients.A comparative evaluation of properties and clinical efficacy of the echinocandins.Clinical pharmacology of antifungal agents in pediatric patients.Current options in antifungal pharmacotherapy.Experiences with the use of caspofungin in paediatric patients.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation.Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report.Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin.Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.Interactions between anti-infective agents and immunosuppressants in solid organ transplantation.Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT.Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A.Early clinical experience with anidulafungin at a large tertiary care medical center.Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis.Pharmacology of Systemic Antifungal AgentsPharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins
P2860
Q28273738-B8221C81-4F49-4B9B-A806-A0F29C98695AQ30319559-5D3A9477-98E0-488D-963A-5FF50EC93F39Q33232599-F64800EC-E3A7-465B-841E-14EF43651140Q34151170-2F7A944F-3FA0-4A35-92A5-BA82268DFBAEQ35959484-0112771E-1688-4C2A-A540-ECF5CAFCDD2AQ35959489-7FB07E46-1A61-4B59-8F97-023BBF63D22EQ36176371-416BD22A-5F73-44F0-AF24-46A41104D5C8Q36222035-8AF02CB4-F3EA-496A-84F1-61A95C3A89CFQ36271648-CBD70A5E-A99C-491A-9555-F6063689AC03Q36278031-75B39E27-3C26-4D5D-883C-E2A95468CFE1Q36382578-553A3AEB-C7F9-4BC3-8B25-FF42D9BAC577Q36441524-5956F698-F47A-42D3-80B6-9F929364EABFQ36458402-BF88C94B-7FA6-437C-AE01-4D172866BA6BQ36484945-6CDD0974-12BD-4B6A-83D1-C4A4A0D8431AQ36505508-DE696B69-D340-4B25-A799-3F5E605EB0B9Q36626518-3A0CACFE-E805-4620-B520-6A499CACB650Q36742397-40A93C2A-CC9F-47EA-B376-735587C5E78FQ36872848-7B02ED28-0D5F-48C7-8B93-0EA8E4AE1183Q36895839-CE8999C9-6611-40DE-8915-B32EA3A9439AQ36968140-F9175BEC-2FC3-43C4-836F-B7814FE251A1Q37151326-9B2210C3-C283-46D0-84BA-4CAC59CDF5C0Q37159589-D8EE3CCE-EAB0-44BF-AA6A-4552888ACC1FQ38284468-01A792F9-5FEA-475F-897F-F7234B25BA64Q38586680-C119645A-7F45-4901-9616-0FBEAC36FAA1Q38838088-140F7FBB-5E42-459A-BF77-71262738109FQ40463769-B94FD558-37BE-496A-B710-B898F1C44E5FQ40489288-CACF030A-26E4-4E01-9A13-A5DDAAAE3293Q40855547-829566C6-FB26-4E8B-85B6-44CB6BC8D4E8Q42272268-A62A4FEC-13EE-47FF-BA41-421FA61C4432Q43233993-8C5C794F-1F73-4B0F-A768-4A1824D51CC6Q44952892-115DDFF3-B4D6-4241-8891-D78C14AA68B3Q46836740-369B8948-9DF2-4FEC-A4B9-5ED254D22C25Q47700700-B8432064-BC66-4FB0-890E-674CFEF05177Q57533011-0124F983-87DC-4039-B7F7-F80DBF4CF3A4Q57746174-42F01155-3682-414A-AA76-E29AD57F316D
P2860
Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Retrospective study of the hep ...... caspofungin and cyclosporin A.
@ast
Retrospective study of the hep ...... caspofungin and cyclosporin A.
@en
type
label
Retrospective study of the hep ...... caspofungin and cyclosporin A.
@ast
Retrospective study of the hep ...... caspofungin and cyclosporin A.
@en
prefLabel
Retrospective study of the hep ...... caspofungin and cyclosporin A.
@ast
Retrospective study of the hep ...... caspofungin and cyclosporin A.
@en
P2093
P2860
P1476
Retrospective study of the hep ...... caspofungin and cyclosporin A.
@en
P2093
G Papanicolaou
J Chodakewitz
J M Arduino
N Kartsonis
P2860
P304
P356
10.1111/J.1399-3062.2004.00065.X
P577
2004-09-01T00:00:00Z